Diagnostic solutions company Perspectum Diagnostics announced on Wednesday a partnership with Singapore imaging centre Precious Medical Centre to provide an accurate method to quantify chronic liver disease and improve quality of care for patients in Asia.
Through the partnership LiverMultiScan, a non-invasive assessment of liver tissue health, is now available at Precious Medical Centre. LiverMultiScan quantifies liver fat, iron and fibro-inflammation, providing additional insight to support the management of chronic liver disease patients and potentially reduce the need for painful biopsies.
Precious Medical Centre in Singapore is the first facility in Asia to offer LiverMultiScan.
Chronic liver disease is a 'silent' and growing epidemic, Perspectum said. Increasing levels of obesity and diabetes have driven a rise in non-alcoholic fatty liver disease (NAFLD). If liver disease is diagnosed early, progression can be limited, reducing the need for expensive interventions.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007